Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Atlas Antibodies on the acquisition of HistoCyte Laboratories
Mandate

Vinge advises Atlas Antibodies on the acquisition of HistoCyte Laboratories

February 15, 2021 Banking and Finance Capital Markets and Public M&A M&A

Vinge advises Atlas Antibodies AB (majority owned by Patricia Industries, a part of Investor AB), in connection with its acquisition of HistoCyte Laboratories Ltd.

HistoCyte Laboratories’ portfolio of cell line materials provide control of immunohistochemical assays used in the diagnosis of cancer. The company has established a significant presence on important markets such as the UK and USA.

Closing is expected during early March 2021.

Vinge’s team consisted of Jonas Johansson together with Viktor Lennartsson (M&A), Albert Wållgren and Josefine Lanker (Banking and Finance) and Clara Sohlberg (Capital Markets and Public M&A).

Related

Vinge advises Morrow Bank AB (publ) in connection with the bank’s sale of parts of MedMera Bank and the sale of NPL portfolios

 Vinge has advised Morrow Bank AB (publ) in connection with the divestment of parts of MedMera Bank’s operations to a leading global credit investment firm. The divestment is structured as a sale of shares and priced at a premium of approximately SEK 90 million above equity value as per the completion date. The transaction includes parts of MedMera’s banking operations such as IT infrastructure, organisation and management, whilst Morrow Bank retains MedMera’s performing loans, deposits, customers, the MedMera brand, the Coop partnership agreement as well as key personnel.
September 15, 2026

Vinge advises HealthCap in conjunction with its investment in AMRA Medical

 HealthCap is investing in AMRA Medical AB, a company that analyses whole-body MRI images to classify and quantify an individual’s muscle and fat tissue throughout the body and places this in relation to human health and disease.
September 15, 2026

Vinge has advised EQT managed Scaleup Europe Fund on its investment in Tandem Health

 Vinge has advised EQT managed Scaleup Europe Fund as lead investor in Tandem Health's USD 100 million Series B investment round, with participation from existing investors Kinnevik, Northzone, Amino Collective and Visionaries. Tandem Health is an AI healthcare company founded in 2023 and headquartered in Sweden. Tandem Health operates as an AI partner within the healthcare sector across Europe, providing AI medical assistant support to clinicians in connection with patient visits.
September 15, 2026